Griseofulvin Powder (microsize)  
FOR ORAL USE IN HORSES

ANADA 200-391, Approved by FDA

MADE IN USA

CAUTION
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS
Equine ringworm infection caused by Trichophyton equinum or Microsporum gypseum.

DESCRIPTION
Griseofulvin Powder (microsize) is available in 15-gram packets each containing 2.5 grams griseofulvin (microsize). Griseofulvin Powder (microsize) is an orally effective antifungal antibiotic specifically active against superficial fungi which cause tinea (ringworm) of the skin and hair. This microsize form of griseofulvin differs from regular Griseofulvin Powder products in that its finer particle size results in a much greater surface area for absorption. An increased blood level has been obtained in experimental studies in man using fine particle size griseofulvin, indicating better absorption and a greater amount of the drug available for fungistatic action in the skin and hair.

BENEFITS
- **Orally Effective Antifungal Treatment**: Specifically active against superficial fungi which cause tinea (ringworm) of the skin and hair.
- **Microsized**: Finer particle size provides greater surface area for absorption and drug available for fungistatic action in the skin and hair.
- **Economical**: Available in 15-gram packet sizes (2.5 grams Griseofulvin).
- **Ease of Use**: Powder may be given on a small amount of feed or in a drench.
- **Usual Dose**: One half to one packet daily.
- **Safe**: Approved by FDA.

PACKAGING

<table>
<thead>
<tr>
<th>LIST NO.</th>
<th>UNIT PACKAGE</th>
<th>CASE SIZE</th>
<th>PALLET</th>
</tr>
</thead>
<tbody>
<tr>
<td>1GRI001</td>
<td>15 g pouch</td>
<td>96 (8 x 12)</td>
<td>5,760</td>
</tr>
</tbody>
</table>

WARNING
Do not use in horses intended for human consumption.

See reverse side for Technical Information.
GENERAL CONSIDERATIONS:
In human medicine, Griseofulvin Powder (microsize) is indicated in the treatment of infections caused by dermatophytic fungi of the skin, hair, and nails. Of those organisms which cause these conditions, the following are responsive to oral therapy with Griseofulvin Powder (microsize): Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton schoenleinii, Trichophyton sulphureum, Trichophyton verrucosum, Trichophyton interdigitale, Epidermophyton floccosum, Microsporum gypseum, Microsporum canis, Microsporum audouinii. Griseofulvin Powder (microsize) is inactive against bacteria and yeasts including Monilia, Actinomyces, Nocardia, Blastomyces, Coccidioides, Histoplasma, Cryptococcus, Sporotrichum, and Aspergillus.

The Griseofulvin Powder (microsize) product is administered orally until the fungi have been eliminated from the skin and hair. The length of therapy will vary with the severity of the infection. The time necessary for the newly formed, fungal-resistant keratin to reach the surface varies greatly with different structures, such as hair and thin body skin. Experimental and clinical work indicates that animals showing involvement of skin and hair only may require treatment for 3 to 4 weeks. Cure is considered complete when repeated cultures are negative for the presence of fungi. In the absence of these tests, therapy should be continued until lesions are clinically improved and there is evidence of resumed hair growth.

The infected skin in many cases shows a remarkably rapid improvement, with decreased itching and inflammation occurring in a few days. In some cases the skin may appear normal clinically in as short a time as 10 days. Viable fungi in the outer layers may persist, however, and the possibility of reinfection is not known with certainty. The optimal period of treatment has not yet been determined. Clipping of the hair to help remove any remaining viable fungi is indicated. Hair that is clipped from the infected lesion should be burned.

INDICATIONS:
Equine - Ringworm infection caused by Trichophyton equinum and Microsporum gypseum.
Adults - 1 packet per day (2.5 grams).
Yearlings - 1/2 to 1 packet per day (1.25-2.5 grams).
Foals - 1/2 packet per day.

Cases of ringworm in horses caused by T. equinum and M. gypseum should be treated with the Griseofulvin Powder (microsize) product for a period of not less than 10 days. Responsive cases may show clinical signs of recovery in 5 to 7 days after griseofulvin therapy is initiated. In responsive cases, treatment should be continued until all infected areas are negative by appropriate culture.

If cases do not respond to therapy in 3 weeks, it is recommended that the diagnosis be reevaluated.

The powder may be given on a small amount of feed or in a drench.

WARNING:
Do not use in horses intended for human consumption.

The safety and efficacy of prophylactic use of griseofulvin has not been established. This drug should not be used to treat minor or trivial infections.

Safety of griseofulvin for use in pregnant animals has not been established. This drug should not be used in horses intended for human consumption. The safety and efficacy of prophylactic use of griseofulvin has not been established. This drug should not be used to treat minor or trivial infections.

STORAGE:
Store between 2°C and 30°C (36°F and 86°F).

To obtain an MSDS or for assistance, contact Bimeda, Inc. at 1-888-524-6332.